An orally bioavailable allele-selective mutant ATXN1 degrader ameliorates motor and cognitive deficits in a humanized SCA1 knock-in model

Spinocerebellar ataxia type 1 (SCA1) is a monogenic fatal neurodegenerative disorder that currently has no disease-modifying therapies. SCA1 is mainly driven by the accumulation of mutant Ataxin-1 protein (mATXN1) containing an expanded polyglutamine (polyQ) stretch, whereas its wild-type version (wtATXN1) has important neuronal and molecular functions. Similar scenarios apply to other polyQ diseases, such as Huntington’s disease (HD) and several other types of SCAs. Thus, allele-selective mATXN1 lowering with orally available small molecule compounds is highly desirable, in order to avoid deleterious consequences of wtATXN1 depletion. Here, we identified the compound 715, a novel oxindole-derived, brain-penetrant, and orally available degrader that lowers both soluble and aggregated mATXN1 in an allele-selective manner. Mechanistically, 715 enhanced proteasomal but not autophagic degradation of mATXN1 by elevating its poly-ubiquitination. A ubiquitin-focused CRISPR screen identified BIRC7 as the primary E3 ligase mediating 715-induced mATXN1 poly-ubiquitination and clearance. Intraperitoneal administration of 715 significantly reduced cerebellar mATXN1 by 40-60% within 10 days and partially rescued motor deficits over 30-day dosing in Atxn1154Q/2Q knock-in mice. To improve translational assessment, we generated and characterized a humanized Atxn1h60Q/2Q knock-in model carrying a clinically representative polyQ length (60Q), in which 715 lowered endogenous mATXN1 and substantially improved motor coordination, spatial learning, and cerebellar Purkinje cell pathology. Notably, a 40-day oral dosing regimen of 715 achieved 30-40% cerebellar mATXN1 clearance and comparable functional rescue with a favorable long-term safety profile, highlighting the translational potential of the allele-selective lowering of mATXN1, even to a modest degree. Together, we identified 715 as an orally active therapeutic lead compound, providing potential new entry points for SCA1 treatment.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11461952/v1
Primary Topic
Genetic Neurodegenerative Diseases
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

An orally bioavailable allele-selective mutant ATXN1 degrader ameliorates motor and cognitive deficits in a humanized SCA1 knock-in model

Boxun Lu, David Chaim Rubinsztein, Xuanle Ji, Yuhua Fu et al.
Research Square
Genetic Neurodegenerative Diseases
preprint

An orally bioavailable allele-selective mutant ATXN1 degrader ameliorates motor and cognitive deficits in a humanized SCA1 knock-in model

Boxun Lu, David Chaim Rubinsztein, Xuanle Ji, Yuhua Fu, Yimin Sun, Yinkun Luo, Jian Wang, Jiayu Chen, Hailiang Tan
preprint en

Abstract

Spinocerebellar ataxia type 1 (SCA1) is a monogenic fatal neurodegenerative disorder that currently has no disease-modifying therapies. SCA1 is mainly driven by the accumulation of mutant Ataxin-1 protein (mATXN1) containing an expanded polyglutamine (polyQ) stretch, whereas its wild-type version (wtATXN1) has important neuronal and molecular functions. Similar scenarios apply to other polyQ diseases, such as Huntington’s disease (HD) and several other types of SCAs. Thus, allele-selective mATXN1 lowering with orally available small molecule compounds is highly desirable, in order to avoid deleterious consequences of wtATXN1 depletion. Here, we identified the compound 715, a novel oxindole-derived, brain-penetrant, and orally available degrader that lowers both soluble and aggregated mATXN1 in an allele-selective manner. Mechanistically, 715 enhanced proteasomal but not autophagic degradation of mATXN1 by elevating its poly-ubiquitination. A ubiquitin-focused CRISPR screen identified BIRC7 as the primary E3 ligase mediating 715-induced mATXN1 poly-ubiquitination and clearance. Intraperitoneal administration of 715 significantly reduced cerebellar mATXN1 by 40-60% within 10 days and partially rescued motor deficits over 30-day dosing in Atxn1154Q/2Q knock-in mice. To improve translational assessment, we generated and characterized a humanized Atxn1h60Q/2Q knock-in model carrying a clinically representative polyQ length (60Q), in which 715 lowered endogenous mATXN1 and substantially improved motor coordination, spatial learning, and cerebellar Purkinje cell pathology. Notably, a 40-day oral dosing regimen of 715 achieved 30-40% cerebellar mATXN1 clearance and comparable functional rescue with a favorable long-term safety profile, highlighting the translational potential of the allele-selective lowering of mATXN1, even to a modest degree. Together, we identified 715 as an orally active therapeutic lead compound, providing potential new entry points for SCA1 treatment.

Research Square
University of Cambridge (GB), Fudan University (CN), Huashan Hospital (CN)
Genetic Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon